2020 NATIONAL SURVEY ON DRUG USE AND HEALTH (NSDUH): FINAL CAI SPECIFICATIONS FOR PROGRAMMING Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality Rockville, Maryland 20857 Last Revised: October 31, 2019 2020 NATIONAL SURVEY ON DRUG USE AND HEALTH (NSDUH): FINAL CAI SPECIFICATIONS FOR PROGRAMMING Contract No. HHSS283201700002C RTI Project No. 0215638.020.019.102.001 RTI Authors: RTI Project Director: Emily Geisen David Hunter Gretchen McHenry Larry Kroutil SAMHSA Project Officer: Peter Tice For questions about this report, please email [email protected]. Prepared for Substance Abuse and Mental Health Services Administration, Rockville, Maryland Prepared by RTI International, Research Triangle Park, North Carolina Last Revised: October 31, 2019 Recommended Citation: Center for Behavioral Health Statistics and Quality. (2019). 2020 National Survey on Drug Use and Health (NSDUH): CAI Specifications for Programming (English Version). Substance Abuse and Mental Health Services Administration, Rockville, MD. Acknowledgments This publication was developed for the Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Behavioral Health Statistics and Quality (CBHSQ), by RTI International, a trade name of Research Triangle Institute, Research Triangle Park, North Carolina, under Contract No. HHSS283201700002C. Significant other contributors to this document at RTI include Rebecca Granger and David Hunter, who were reviewers. Contributors to this report from CBHSQ include Barbara Forsyth, Grace Medley, and Laura J. Sherman. Content of 2020 NSDUH Instrument # Module Mode of Administration Required Aids Page 1. Introduction CAPI* None 1 2. Core Demographics CAPI Showcards 1-5 3 3. Beginning ACASI Section FI reads description of keyboard and None 13 helps respondent adjust headphones. 4. Tutorial Respondent completes computer None 15 practice session with FI help. 5. Calendar (30-day and 12-month reference dates) ACASI** None 19 6. Tobacco ACASI None 21 7. Alcohol ACASI None 55 8. Marijuana ACASI None 71 9. Cocaine ACASI None 83 10. Crack ACASI None 95 11. Heroin ACASI None 107 12. Hallucinogens ACASI None 119 13. Inhalants ACASI None 173 14. Methamphetamine ACASI None 189 15. Pain Relievers Screener ACASI None 201 16. Tranquilizers Screener ACASI None 209 17. Stimulants Screener ACASI None 213 18. Sedatives Screener ACASI None 219 19. Pain Relievers Main Module ACASI None 223 20. Tranquilizers Main Module ACASI None 275 21. Stimulants Main Module ACASI None 309 22. Sedatives Main Module ACASI None 353 23. Special Drugs ACASI None 389 24. Risk/Availability Section ACASI None 397 25. Blunts ACASI None 403 26. Definitions for Use in the Drugs Module ACASI None 411 27. Substance Dependence and Abuse ACASI None 415 28. Special Topics ACASI None 535 29. Prior Substance Use ACASI None 541 30. Drug Treatment ACASI None 599 31. Health ACASI None 627 32. Adult Mental Health Service Utilization ACASI None 647 33. Social Environment ACASI: 18+ year-olds only None 659 34. Parenting Experiences ACASI: parents of 12-17-year-olds None 661 35. Youth Experiences ACASI: 12-17-year-olds only None 665 36. Mental Health ACASI: 18+ year-olds only None 679 37. Adult Depression ACASI: 18+ year-olds only None 689 38. Youth Mental Health Service Utilization ACASI: 12-17-year-olds only None 707 39. Adolescent Depression ACASI: 12-17-year-olds only None 721 40. Definitions for Use in Consumption of Alcohol ACASI None 739 Module 41. Consumption of Alcohol ACASI None 741 42. Emerging Issues ACASI None 751 43. Market Information for Marijuana ACASI None 767 44. Back End Demographics ACASI None 783 45. Education ACASI None 787 46. Employment ACASI None 793 47. Household Roster CAPI Showcards 6&7 801 48. Proxy Information CAPI None 813 49. Health Insurance CAPI (Proxy allowed) Showcards 8&9 827 50. Income CAPI (Proxy allowed) Showcards 10-12 834 51. Verification FI & respondent complete form. Verification Form 849 * CAPI (computer-assisted personal interviewing): FI reads questions and records responses. ** ACASI (audio computer-assisted self-interviewing): Respondent reads questions on screen or listens to questions through headphones and then records answers into computer. 2020 NATIONAL SURVEY ON DRUG USE AND HEALTH CAI INSTRUMENT REVISIONS Clinical Validation Study The Clinical Validation Study (CVS) was embedded within the first six months of 2020 National Survey on Drug Use and Health (NSDUH) main study data collection to assess the updated substance use disorders (SUD) module, which has been revised to be consistent with the Diagnostic and Statistical Manual of Mental Disorders (DSM), fifth edition criteria (DSM-5). The CVS sample was comprised of a probability subsample of Adults aged 18 and older and Youth aged 12-17, selected from NSDUH main study interview respondents who answered the survey in English and reported using alcohol or marijuana at least once in the past 12 months. NSDUH main study interview respondents selected for the CVS were assigned the DSM-5 SUD module in place of the DSM-IV SUD module, but otherwise completed modules in the same order as other NSDUH main study interview respondents. Summary of Revisions Changes to the specifications to accommodate the CVS are noted in yellow highlighting. Changes between the 2019 NSDUH and 2020 NSDUH are noted in green and blue highlighting. Green revisions indicate that a question or logic was moved one location in the questionnaire to aother location. Blue highlighting indicates revisions. General CAI Issues • Updated all interviewer notes to follow the current CAI convention that text in ALL CAPS should not be read to a respondent. Introduction • Page 1: CAI version number and expiration date will be updated. Pain Relievers Main Module • Pages 228 and 235: Edited the definitions of PRJANFLAG1, PRDECFLAG1, PR1MTHFLAG1, PRJANFLAG2, PRDECFLAG2, and PR1MTHFLAG2 in the specifications only to better represent existing CAI program functions. • Pages 228 and 235: Updated the logic in PRY01d and PRY02d due to edited definitions earlier in this module. Tranquilizers Main Module • Pages 279 and 286-287: Edited the definitions of TRJANFLAG1, TRDECFLAG1, TR1MTHFLAG1, TRJANFLAG2, TRDECFLAG2, and TR1MTHFLAG2 in the specifications only to better represent existing CAI program functions. • Pages 279 and 287: Updated the logic in TRY01d and TRY02d due to edited definitions earlier in this module. i Stimulants Main Module • Pages 313 and 320-321: Edited the definitions of STJANFLAG1, STDECFLAG1, ST1MTHFLAG1, STJANFLAG2, STDECFLAG2, and ST1MTHFLAG2 in the specifications only to better represent existing CAI program functions. • Pages 313-314 and 321: Updated the logic in STY01d and STY02d due to edited definitions earlier in this module. Sedatives Main Module • Pages 357 and 364-365: Edited the definitions of SVJANFLAG1, SVDECFLAG1, SV1MTHFLAG1, SVJANFLAG2, SVDECFLAG2, and SV1MTHFLAG2 in the specifications only to better represent existing CAI program functions. • Pages 357-358 and 365: Updated the logic in SVY01d and SVY02d due to edited definitions earlier in this module. Definitions for Use in the Drugs Modules • Page 411: Added logic to determine which respondents were eligible and selected for the CVS sample. • Page 411: Created new definitions for AL12MON2 and MJ12MON2 to allow CVS respondents who used alcohol or marijuana at least once in the past year to receive the DSM-5 SUD modules for the substances they used. • Page 413: Moved the definition of COKEFILL from the Substance Dependence and Abuse module to Definitions for Use in the Drugs Modules Substance Dependence and Abuse • Page 415: Added logic to route respondents in the CVS sample to DSM-5 SUD and all other eligible respondents to INTRODR. • Pages 459-460: Updated the logic in the specifications for DRST to match the logic used in the CAI. • Pages 464-465: Updated the logic in the specifications for DRSV to match the logic used in the CAI. • Page 471: Added the DSM-5 SUD module for use in the Clinical Validation Study. Emerging Issues • Pages 751-766: Created a new module, Emerging Issues, which combines existing questions on recovery, medication-assisted treatment questions, and kratom, with new questions on vaping, synthetic marijuana, and synthetic stimulants. • Pages 758-759: Added lifetime and recency questions about vaping anything and vaping nicotine or tobacco. ii • Page 759: Added lifetime and recency questions on synthetic marijuana. • Page 760: Added lifetime and recency questions on synthetic stimulants. • Pages 760-766: Added questions in concordance with the DSM-5 to measure occurrence of marijuana withdrawal symptoms, occurrence of prescription tranquilizer misuse withdrawal symptoms, and occurrence of “craving” for all substances. Market Information for Marijuana • Pages 767-769 and 775: Revised the response options for MJE01, MJE06 and MJE36 to better accommodate self-administration. • Pages 767-768: Added a question (MJE05b) about purchasing marijuana from a store or dispensary • Pages 770 and 777: Clarified that question MJE14 and MJE44 are asking about how much marijuana the respondent bought in loose form the last time they bought marijuana. • Page 773: Updated logic for questions (MJE26, MJE27, and MJE28) asking about setting details for the last time marijuana was purchased to exclude respondents who last purchased marijuana from a store or dispensary. Health Insurance • Pages 827-830: Medicaid and CHIP names will be updated to reflect annual